America’s biopharmaceutical companies are committed to finding solutions to help the millions affected by COVID-19. In addition to applying their scientific expertise to find ways to diagnose, treat and prevent infections from the virus, the biopharmaceutical industry is providing financial support and in-kind donations to organizations and collaborating with U.S. and global health authorities to combat this global public health emergency.

Our Commitment to Beat Coronavirus

In these unprecedented times, we are coming together to achieve one shared goal: to beat COVID-19. The decades-long investments we have made in new technology, research and treatments have prepared us to act swiftly:

• We are rapidly screening our vast global libraries of medicines to identify potential treatments and have numerous clinical trials underway to test new and existing therapies
• We are dedicating our top scientists and using our investments in new technologies to speed the development of safe and effective vaccines
• We are sharing the learnings from clinical trials in real time with governments and other companies to advance the development of additional therapies
• We are expanding our unique manufacturing capabilities and sharing available capacity to ramp up production once a successful medicine or vaccine is developed
• We are collaborating with government agencies, hospitals, doctors and others to donate supplies and medicines to help those affected around the world
• We are working with governments and insurers to ensure that when new treatments and vaccines are approved they will be available and affordable for patients

Supporting those on the Frontlines

In addition to researching and developing potential treatments and vaccines, PhRMA member companies are committed to supporting health care workers who are on the frontlines and communities around the world affected by COVID-19 by:

• Providing personal protective equipment (PPE) and medical supplies to protect our health care workforce and offering donations of existing medicines that may be effective in treating patients with the virus
• Donating millions of dollars (among other currencies) and in-kind support to support organizations at the heart of the crisis that directly impact infected patients and communities.
• Creating programs empowering employees with medical or laboratory expertise to completely or partially pause their current roles and volunteer their medical skills to help their local health care organizations.